NTLA Investors Have the Opportunity to Lead the Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Intellia Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's drug development programs [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $50,000 in Intellia between July 30, 2024, and January 8, 2025, to discuss their legal rights [1]. - There is an April 14, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Intellia [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Company Developments and Financial Impact - Intellia's complaint alleges that the company and its executives made false statements regarding the Phase 1/2 study of NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [4]. - On January 9, 2025, Intellia announced a strategic shift, focusing on drug candidates NTLA-2002 and nex-z, while discontinuing NTLA-3001, leading to a workforce reduction of approximately 27$1.82 per share, or 15.14%, closing at $10.20 per share on January 10, 2025 [6].